Palantir shares slip by 7% despite posting record revenue in third quarter
Investing.com - Wolfe Research raised its price target on Guardant Health (NASDAQ:GH) to $90.00 from $75.00 on Thursday, while maintaining an Outperform rating on the stock. Guardant shares currently trade at $72.27, having surged over 213% in the past year and sitting just 1% below their 52-week high.
The research firm cited Guardant Health ’s ownership of blood-based colorectal cancer (CRC) screening, therapy selection, and minimal residual disease (MRD) detection technologies as key factors in the decision. These technologies have helped drive the company’s impressive 28.74% revenue growth over the last twelve months.
Wolfe Research noted that Guardant has successfully reinvigorated growth in its market-leading G360 franchise through an expanded panel and increased repeat testing.
The firm also highlighted Guardant’s progress in advancing its Shield product in CRC screening and positioning its Reveal product as the leading tumor-agnostic MRD player.
Wolfe Research’s sum-of-the-parts valuation reached approximately $90 per share, with the firm allocating only about $5 per share to the Shield product in its analysis. This target sits above the current analyst consensus range of $47-$85, though InvestingPro data suggests the stock may be overvalued compared to its Fair Value. Investors seeking deeper insights can access the comprehensive Pro Research Report, available for Guardant Health and 1,400+ other US equities through InvestingPro.
In other recent news, Guardant Health reported its third-quarter 2025 earnings, surpassing market expectations with a notable performance. The company posted an earnings per share (EPS) of -$0.39, significantly beating the forecasted -$0.79, which resulted in a 50.63% earnings surprise. Revenue also exceeded projections, reaching $265.2 million compared to the expected $235.64 million, marking a 12.54% surprise. Following these results, BTIG raised its price target for Guardant Health to $100 from $80, maintaining a Buy rating. This adjustment came after the company delivered a 12% top-line beat and increased its guidance beyond the beat amount. These developments reflect a positive outlook from analysts and investors alike.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.